

Amendments to the Claims

Please amend Claims 1, 3, 14 and 16-18. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of suppressing or eliminating tumor cells, comprising administering to a subject in need of suppressing or eliminating tumor cells a neutral soluble glucan and at least one complement activating anti-tumor antibody directed to the tumor cells or antigens of said tumor cells, wherein the glucan does not induce systemic release of inflammatory cytokines and the glucan and antibody together suppress or eliminate tumor cells.
2. (Previously Presented) The method of claim 1, wherein the antibody is introduced via direct administration of monoclonal or polyclonal antibodies.
3. (Currently Amended) The method of claim 1, wherein the antibody is selected from ~~the group consisting of:~~ trastuzumab, rituximab, cetuximab ~~and~~ or combinations thereof.
4. (Original) The method of claim 1, wherein the soluble beta glucan is administered parenterally.
- 5-13. (Canceled)
14. (Currently Amended) The method of claim 1, wherein the neutral soluble glucan is in a single helix conformation, a triple helix conformation, or a combination[[s]] thereof.
15. (Canceled)
16. (Currently Amended) A method of suppressing or eliminating tumor cells, comprising administering a neutral soluble glucan and trastuzumab to a subject in need of suppressing or eliminating tumor cells, wherein the glucan does not induce systemic

release of inflammatory cytokines and the glucan and trastuzumab together suppress or eliminate tumor cells.

17. (Currently Amended) A method of suppressing or eliminating mammary carcinoma, comprising administering a neutral soluble glucan and trastuzumab to a subject having mammary carcinoma, wherein the glucan does not induce systemic release of inflammatory cytokines and the glucan and trastuzumab together suppress or eliminate mammary carcinoma.
18. (Currently Amended) A method of regressing tumor growth, comprising administering a neutral soluble glucan and trastuzumab to a subject having a tumor to regress tumor growth, wherein the glucan does not induce systemic release of inflammatory cytokines.